What does the GMC expect around prescribing unlicensed medicines?

Prescribing a medicine that is not licensed for a particular use can sometimes be clinically appropriate. But it is not a shortcut around the usual standards of care. The General Medical Council (GMC) expects doctors to make a sound clinical decision, explain the relevant uncertainties, obtain the patient’s agreement and take responsibility for care after prescribing.

For private clinics, meeting those expectations is both a clinical and an operational responsibility. Patients need to understand why a medicine is being considered, what other options they have, what it will ongoing care plan private clinic cost and what https://seo.edu.rs/blog/why-do-patients-ask-the-same-questions-through-different-channels-11226 happens after the first appointment. A clear clinic website and online booking process can support that understanding before a patient commits to care.

This article summarises key principles in the GMC’s guidance on prescribing and managing medicines. It is general information, not a substitute for current GMC guidance, professional advice or the clinician’s judgement in an individual case.

What counts as an unlicensed medicine?

A medicine is generally described as unlicensed when it does not have a UK marketing authorisation for the product or circumstances in question. This may include a medicine made to meet a specific patient’s needs, or a medicine used in a way that falls outside the terms of its licence.

These situations are not all the same. In particular, a medicine may be licensed in the UK but prescribed “off-label”—for example, for a different condition, dose, age group or route than its licence specifies. An unlicensed medicine may have no relevant UK licence at all. The distinction matters because the clinical evidence, supply arrangements and explanation to the patient may differ.

Neither “unlicensed” nor “off-label” automatically means that a treatment is unsuitable. Nor does it mean the treatment is proven or appropriate. The prescriber must consider the circumstances, the available evidence and the patient’s needs. The GMC’s central concern is that the decision is clinically justified and the patient is properly informed.

The GMC’s core expectations for safe prescribing standards

The GMC expects doctors to prescribe in the patient’s best interests and to be able to justify their decisions. When considering an unlicensed medicine, a doctor should not rely on a general claim that it is innovative, widely used or requested by the patient. The decision needs a clinical rationale for that person.

In practice, safe prescribing standards include the following:

• Assess the patient properly. Understand their symptoms, relevant medical history, current medicines, allergies, previous treatment and any factors that could affect safety.
• Consider the available options. This may include licensed treatments, non-medicine approaches, further investigation, referral, or deciding that treatment is not currently appropriate.
• Use evidence and expertise. Consider the quality and relevance of available evidence, recognised guidance and your own competence. Seek advice where the decision is outside your expertise.
• Make an individual clinical judgement. Consider whether the likely benefits justify the risks and uncertainties for this patient, rather than treating a product or pathway as suitable for everyone.
• Explain the decision and agree a plan. Give the patient enough clear information to make an informed choice, including what will happen if treatment is ineffective or causes problems.
• Keep an adequate record. Document the assessment, the reasons for prescribing, relevant discussions, consent, instructions and the monitoring plan.

A clinic’s process should make space for these steps. A short online form or booking questionnaire may collect useful background, but it should not be presented as a substitute for a clinical assessment. The clinician must still decide whether the information is sufficient and whether further questions, examination or records are needed.

Assessment comes before the prescription

Patients may arrive with a strong preference, information from online forums or a view that a particular medicine is the answer. Listening to that perspective is important, but the assessment must remain clinically led. A prescription should not be treated as a guaranteed outcome of paying for an appointment.

Before prescribing, the clinician should consider whether the patient’s diagnosis or presentation is sufficiently clear, whether there are contraindications or interactions, and whether another explanation or treatment deserves attention. If the available information is incomplete, the appropriate next step may be to request records, arrange an examination, seek specialist input or defer a decision.

That process should be understandable to the patient. “We need more information” is more useful when the clinic explains what is missing, why it matters, how it will be obtained and whether it will involve another charge. Similarly, if the clinician decides not to prescribe, the patient should receive a clear explanation and practical advice about next steps where appropriate.

Explain options without overwhelming patients

Informed agreement is not achieved by handing someone a dense list of risks or asking them to sign a form they have not understood. The GMC expects relevant information to be discussed in a way the patient can understand. That includes explaining that a medicine is unlicensed or being used off-label, as applicable, and what this means in their circumstances.

A useful conversation covers:

• why the clinician is considering this medicine for this patient;
• what is known—and not known—about its benefits and risks for the proposed use;
• reasonable alternatives, including no medicine or no immediate treatment;
• how the medicine will be supplied, used and reviewed;
• what symptoms or side effects should prompt the patient to seek advice; and
• what happens if the treatment does not help or is not tolerated.

To avoid overwhelming patients, clinics can present information in layers. Start with a plain-English summary and the choices that matter now. Then provide written detail for patients who want to read more, and invite questions before a decision is made. Avoid promising outcomes before assessment or describing a treatment as “personalised” without explaining what is actually individualised—for example, the assessment, choice of dose, review schedule or decision to stop.

Prescribing also means taking responsibility for follow-up

A prescription is not the end of the clinician’s responsibility. The GMC expects doctors to make suitable arrangements for monitoring and review, particularly where treatment is new to the patient, requires dose adjustment or has meaningful risks. This ongoing care responsibility should be clear before the patient starts treatment.

A monitoring and follow-up plan should set out who will review the patient, when the review is due, what will be assessed and how the patient can raise a concern between appointments. It should also explain what to do if symptoms worsen, an adverse effect occurs or the medicine is unavailable. Where responsibility is shared between clinicians or organisations, the handover and division of responsibilities need to be explicit.

Clinics should avoid vague promises such as “ongoing support included” unless they explain what support means. Does it include a scheduled review, prescription queries, dose changes, or only an administrative contact? Patients should know which channel to use and what response arrangements to expect. This is especially important after payment: patients should not have to work out for themselves whom to contact when a clinical issue arises.

Transparent pricing across the full care journey

Clinical decisions must not be driven by commercial interests. At the same time, clear pricing helps patients make an informed choice and protects trust. If the first appointment is only one part of the pathway, the clinic should say so before the patient books.

Explain the likely costs and what is included, such as the initial assessment, any follow-up consultations, tests, prescriptions, medicine, delivery or administrative charges. If the total cost depends on the clinical outcome, say which parts are variable and when the patient will receive that information. Avoid presenting an introductory appointment price in a way that obscures foreseeable costs later in care.

Care stage What patients should be told Before booking Appointment price, what it covers, how the assessment works and whether further steps may incur charges. After assessment The recommended options, expected costs, uncertainties and whether the patient can take time to decide. During treatment Medicine and supply costs, review fees, monitoring arrangements and how to get clinical help. If treatment changes Any new costs, the reason for the change and what happens if the patient chooses not to continue.

Patients may compare providers, including specialist services such as Releaf, while trying to understand the whole pathway rather than just the initial consultation. If a patient explores payment support from a company such as Funding Guru, that is a separate financial decision: it does not determine clinical suitability or replace a clear explanation of the clinic’s own fees and terms. Clinics should present any finance arrangements accurately and make clear who provides them.

Make the clinic website and booking process work together

The clinic website should answer the questions a patient needs to consider before booking, not simply encourage them to start. A concise page can explain what “unlicensed” or “off-label” means, that an assessment does not guarantee a prescription, what information the clinician may need and how follow-up works.

The online booking process should reinforce that information at the point of decision. For example, it can confirm the appointment fee, explain what is included, set out any likely additional costs and provide a route for accessibility or clinical questions. Avoid asking patients to make a treatment choice or accept uncertain costs before a clinician has assessed them.

Useful content is specific. Instead of “we provide personalised care”, explain what the patient can expect: an individual assessment, a discussion of alternatives, a documented decision and an agreed review plan. Instead of “contact us for support”, give the correct clinical contact route and explain when to use it.

A practical clinic checklist

1. Check that clinicians understand the relevant GMC guidance and work within their competence.
2. Build an assessment process that captures clinically relevant information without treating a form as the decision-maker.
3. Record why an unlicensed or off-label option is appropriate, including alternatives and the patient discussion.
4. Give patients clear, balanced information and time to ask questions or decide.
5. Agree who is responsible for prescribing, monitoring and responding to concerns.
6. Publish fees and likely additional costs across the care journey, not just the entry price.
7. Review website and booking wording for vague promises, hidden charges and unclear contact routes.

Trust is built after the appointment, too

Prescribing an unlicensed medicine calls for careful clinical judgement, honest communication and a credible plan for review. The GMC expects the doctor to be able to explain why the choice is in the patient’s interests and how risks will be managed. Patients, meanwhile, need to know what is uncertain, what alternatives exist, what they will pay and who will support them afterwards.

When those details are visible across the clinic website, booking process and consultation, trust becomes more than a marketing phrase. It is a practical asset built through clear decisions, transparent pricing and reliable ongoing care.